Healthcare / BiotechnologyTokyo
$1521.00
-137.00 (-8.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-1.1B · quality 65.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$34.8B
P/E
183.5x
↑EV/EBITDA
81.4x
↑ROE
2.6%
↑Gross Margin
100.0%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+82.4%
FCF CAGR
—
FCF margin
34.8%
FCF / Net income
5.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.03B · net income $190.6M · FCF $1.05B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.03B | $3.03B | $873.6M | $344.7M | $499.1M |
| Net Income | $190.6M | $190.6M | $-812.7M | $-1.47B | $-1.41B |
| EBITDA | $342.2M | $342.2M | $-776.4M | $-1.45B | $-1.41B |
| EPS | — | — | -49.43 | -66.99 | -64.22 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | 9.0% | 9.0% | -118.9% | -423.4% | -292.3% |
| Net Margin | 6.3% | 6.3% | -93.0% | -427.4% | -283.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Current Ratio | 18.48 | 18.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.05B | $1.05B | $-1.36B | $-1.13B | $-1.92B |
| Returns | |||||
| ROE | 2.6% | 2.6% | -12.3% | -28.0% | -29.9% |
| Valuation | |||||
| P/E | 183.47 | 183.47 | — | — | — |
| EV/EBITDA | 81.42 | 81.42 | — | — | — |
| P/B | 4.82 | 4.82 | 3.12 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 246.4% | 246.4% | 153.4% | -30.9% | — |
| EPS Growth | — | — | 26.2% | -4.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-44.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-49.43 → n/d
Residual
-44.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.